These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2448 related items for PubMed ID: 19671655

  • 1. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial.
    N Engl J Med; 2009 Aug 20; 361(8):756-65. PubMed ID: 19671655
    [Abstract] [Full Text] [Related]

  • 2. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group.
    N Engl J Med; 2009 Aug 20; 361(8):745-55. PubMed ID: 19671656
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.
    J Clin Endocrinol Metab; 2008 Jun 20; 93(6):2149-57. PubMed ID: 18381571
    [Abstract] [Full Text] [Related]

  • 5. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A.
    N Engl J Med; 2016 Oct 20; 375(16):1532-1543. PubMed ID: 27641143
    [Abstract] [Full Text] [Related]

  • 6. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
    Moen MD, Keam SJ.
    Drugs Aging; 2011 Jan 01; 28(1):63-82. PubMed ID: 21174488
    [Abstract] [Full Text] [Related]

  • 7. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May 01; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 8. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A.
    N Engl J Med; 2017 Oct 12; 377(15):1417-1427. PubMed ID: 28892457
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Denosumab for treatment of postmenopausal osteoporosis.
    Chitre M, Shechter D, Grauer A.
    Am J Health Syst Pharm; 2011 Aug 01; 68(15):1409-18. PubMed ID: 21785030
    [Abstract] [Full Text] [Related]

  • 11. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M.
    J Clin Endocrinol Metab; 2011 Jun 01; 96(6):1727-36. PubMed ID: 21411557
    [Abstract] [Full Text] [Related]

  • 12. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 16. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M, Gatti D.
    Reumatismo; 2010 May 03; 62(3):163-71. PubMed ID: 21052563
    [Abstract] [Full Text] [Related]

  • 17. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG.
    Osteoporos Int; 2015 Dec 03; 26(12):2773-83. PubMed ID: 26202488
    [Abstract] [Full Text] [Related]

  • 18. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR.
    J Bone Miner Res; 2011 Mar 03; 26(3):530-7. PubMed ID: 20839290
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of osteoporosis with denosumab.
    Lewiecki EM.
    Maturitas; 2010 Jun 03; 66(2):182-6. PubMed ID: 20236778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 123.